Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope
Shares of Eli Lilly and Company rose 0.5% to $1,226.64 early on Thursday, after six lawsuits were filed over alleged illegal sales of retatrutide, the company's experimental drug for obesity. The stock was trading 1.8% below its peak of $1,249.45.